APA (7th ed.) Citation

Sánchez, P., Álamo, C., Almendros, M., Schlueter, M., Tasoulas, A., & Martínez, J. (2023). Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: Results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies. BMC.

Chicago Style (17th ed.) Citation

Sánchez, Pedro, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, and Javier Martínez. Extrapyramidal Adverse Events and Anticholinergics Use After the Long-term Treatment of Patients with Schizophrenia with the New Long-acting Antipsychotic Risperidone ISM®: Results from Matching-adjusted Indirect Comparisons Versus Once-monthly Formulations of Paliperidone Palmitate and Aripiprazole Monohydrate in 52-week Studies. BMC, 2023.

MLA (9th ed.) Citation

Sánchez, Pedro, et al. Extrapyramidal Adverse Events and Anticholinergics Use After the Long-term Treatment of Patients with Schizophrenia with the New Long-acting Antipsychotic Risperidone ISM®: Results from Matching-adjusted Indirect Comparisons Versus Once-monthly Formulations of Paliperidone Palmitate and Aripiprazole Monohydrate in 52-week Studies. BMC, 2023.